TITLE

The Management of Hypertension in the Overweight and Obese Patient: Is Weight Reduction Sufficient?

AUTHOR(S)
Douketis, James D.; Sharma, Arya M.
PUB. DATE
April 2004
SOURCE
Drugs;2004, Vol. 64 Issue 8, p795
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The management of hypertension in the overweight and obese patient is a frequently encountered but under investigated clinical problem. The conventional management of such patients involves weight reduction with dietary therapy or a combined approach with dietary and anti-obesity drug therapy. However, long-term weight reduction, which is necessary to sustain blood pressure (BP) control, is not feasible in over 80% of patients. Anti-obesity therapy with orlistat has inconsistent effects on BP and may benefit only patients who have uncontrolled or non-medicated hypertension. Anti-obesity therapy with sibutramine may be associated with a modest worsening of BP control. Consequently, antihypertensive drug therapy is often required to supplement a weight reduction programme, and also in patients with severe hypertension or hypertension-associated end-organ damage. Treatment with a thiazide diuretic should be considered as first-line antihypertensive drug therapy in overweight and obese patients. ACE inhibitors or non-dihydropyridine calcium channel antagonists are reasonable alternatives where clinically indicated, or they can be used in combination with a thiazide diuretic if treatment with the diuretic alone is insufficient. If such treatment is inadequate for BP control, the addition or substitution of an α- or β-adrenoceptor antagonist may be considered, although the latter can be associated with weight gain. Concurrent disease is an important determinant of first-line and supplementary antihypertensive drug therapy. Additional studies are needed to determine the long-term (>1 year) efficacy and safety of antihypertensive and anti-obesity management strategies in the overweight and obese hypertensive patient.
ACCESSION #
13030350

 

Related Articles

  • Study Shows Weight Loss Program with Xenical Can Also Help Lower Blood Pressure in Obese Hypertensive Patients.  // Ascribe Newswire: Medicine;11/13/2000, p5 

    The article cites a study by researchers at the University of Alabama at Birmingham, Alabama, which holds that weight loss program with xenical can help in lowering blood pressure in obese hypertension patients. Results from a multicoated clinical trial show that weight loss induced by xenical...

  • Pharmacotherapy of Obesity: An Update. Schurgin, Sunita; Siegel, Richard D. // Nutrition in Clinical Care;Jan-Apr2003, Vol. 6 Issue 1, p27 

    There has been an epidemic of obesity in the last decade, In spite of the rising numbers of people who are overweight and obese, medical treatment of obesity is currently where medical treatment of hypertension was in the 1950s with only two Food and Drug Administration-approved medications for...

  • Topiramate withdrawal.  // Reactions Weekly;6/2/2007, Issue 1154, p22 

    The article presents a case report of an obese man who experienced rebound weight gain following topiramate withdrawal. The man had a body mass index of 32 and a history of multiple dietary treatments followed by weight gain and an unsuccessful orlistat treatment. The man stopped further...

  • Orlistat: A Viewpoint by F. Xavier Pi-Sunyer. Pi-Sunyer, F.X. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Mechanism of actio; Toxicity; Effectiveness.

  • Orlistat: A Viewpoint by Madeleine L. Drent. Drent, M.L. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Physiological effects of orlistat; Effectiveness; Adverse effects.

  • Orlistat. McNeely, W.; Benfield, P. // Drugs;Aug1998, Vol. 56 Issue 2, p241 

    â–´ Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity. â–´ Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in...

  • Orlistat.  // Reactions Weekly;9/17/2011, Issue 1369, p30 

    The article describes the case of a woman who developed a lichenoid drug eruption (LDE) following treatment with orlistat for obesity.

  • SECTION 7 METABOLIC DISORDERS.  // MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, p131 

    The article offers information on several drugs for the treatment of obesity. The Belviq weight-loss medication from pharmaceutical firm Eisai Co. Ltd. should be used together with a reduced-calorie diet and weight maintenance to treat obesity. Obese patients are advised to take the Qsymia...

  • Drug for Weight Control Also Lowers BP.  // Clarendon Enterprise (TX);4/17/2008, Vol. 19 Issue 16, p7 

    The article discusses a study published in the "Archives of Internal Medicine" which found that the weight control drug Xenical also helped people with high blood pressure.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics